Our findings support the notion that CXCL13 might be associated with pulmonary vascular remodeling in IPAH and CTEPH, but it is unlikely that serum CXCL13 will be a useful biomarker in these conditions. The gene discussed is CXCL13; the disease is chronic thromboembolic pulmonary hypertension.